Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Submitted by
admin
on July 30, 2012 - 11:06am
Source:
Yahoo
News Tags:
Senesco
SNS01-T
orphan drugs
mantle cell lymphoma
diffuse large B-cell lymphoma
Headline:
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Do Not Allow Advertisers to Use My Personal information
